Drug Trial Radar · NCT04762589
RT001 in Amyotrophic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Mar 10, 2021
Primary completion
Jun 28, 2022
Study completion Jun 28, 2022
Sponsor
- Lead sponsor
- Biojiva LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
RT001Drug
RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
PlaceboDrug
Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the revised ALS Functional Rating Score (ALSFRS-R) at 24 weeksTime frame: 24 weeks
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
University of Tartu
Tartu, Estonia
Riga Stradins Universtiy
Riga, Latvia
UMC Utrecht
Utrecht, Netherlands
Karolinska
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.